Discovery & Development

Sitting Down With… Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.

How unified assay protocols and advanced bioinformatics are refining our understanding of mitochondrial dysfunction in complex diseases.

The industry is under pressure to reduce the risks of nitrosamines in both in-development and on-market drug products.

Proprietary nanovesicles technology has caught the eye of Eli Lilly. We find out why.

Understanding the role of spatially offset Raman spectroscopy in identifying raw materials, counterfeit medicines, and more.

Cell and Gene therapies have come a long way since the 1970s. Technology, combined with knowledge, will take them even further.

What happens when freezers fail? Experts look at the lessons that can be learned from catastrophic power outages.

Unethical practices and forced labor exist in HPMC supply chains. Here’s what can be done about it.

Clinical trials can be needlessly complex – which impacts the bottom line of trial sponsors. It’s time for change.

Immunotherapies can accomplish much, but we can only unlock their true power through collaboration.